Mucositis Stocks List
Symbol | Grade | Name | % Change | |
---|---|---|---|---|
MNPR | D | Monopar Therapeutics Inc. | -2.31 | |
GRTX | F | Galera Therapeutics, Inc. | 2.30 | |
JAZZ | F | Jazz Pharmaceuticals plc | -1.48 |
Related Industries: Biotechnology
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
XPH | D | SPDR S&P Pharmaceuticals ETF | 3.71 | |
PJP | C | PowerShares Dynamic Pharmaceuticals | 3.64 | |
TOKE | F | Cambria Cannabis ETF | 3.5 | |
FTXH | C | First Trust Nasdaq Pharmaceuticals ETF | 2.87 | |
PILL | F | Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF | 2.85 |
Compare ETFs
Date | Stock | Title |
---|---|---|
Jul 1 | JAZZ | Is Jazz Pharmaceuticals plc (JAZZ) the Best Pot Stock to Buy Now? |
- Mucositis
Mucositis is the painful inflammation and ulceration of the mucous membranes lining the digestive tract, usually as an adverse effect of chemotherapy and radiotherapy treatment for cancer. Mucositis can occur anywhere along the gastrointestinal (GI) tract, but oral mucositis refers to the particular inflammation and ulceration that occurs in the mouth. Oral mucositis is a common and often debilitating complication of cancer treatment.Oral and gastrointestinal (GI) mucositis affects almost all patients undergoing high-dose chemotherapy and hematopoietic stem cell transplantation (HSCT), 80% of patients with malignancies of the head and neck receiving radiotherapy, and a wide range of patients receiving chemotherapy. Alimentary tract mucositis increases mortality and morbidity and contributes to rising health care costs.For most cancer treatment, about 5–15% of patients get mucositis. However, with 5-fluorouracil (5-FU), up to 40% get mucositis, and 10–15% get grade 3–4 oral mucositis. Irinotecan is associated with severe GI mucositis in over 20% of patients. Seventy-five to eighty percent of bone marrow transplantation recipients experience mucositis, of which oral mucositis is the most common and most debilitating, especially when melphalan is used. In grade 3 oral mucositis, the patient is unable to eat solid food, and in grade 4, the patient is unable to consume liquids as well.Radiotherapy to the head and neck or to the pelvis or abdomen is associated with Grade 3 and Grade 4 oral or GI mucositis, respectively, often exceeding 50% of patients. Among patients undergoing head and neck radiotherapy, pain and decreased oral function may persist long after the conclusion of therapy. Fractionated radiation dosage increases the risk of mucositis to > 70% of patients in most trials. Oral mucositis is particularly profound and prolonged among HSCT recipients who receive total-body irradiation.
Recent Comments
- TraderMike on Bollinger Band Squeeze
- TraderMike on Bollinger Band Squeeze
- OpenCat584 on Bollinger Band Squeeze
- Dr_Duru on Expansion Breakout
- TraderMike on New Scans: Strong, Oversold Stocks and Weak, Overbought Stocks
From the Blog
Featured Articles